Reimbursement of Medicinal Products containing Teriparatide: Questions and Answers for Healthcare Professionals April 2024

Introduction

In February 2023, following a review of medicinal products containing teriparatide, the HSE-Medicines Management Programme (MMP) identified best-value medicines (BVMs) for teriparatide on the High Tech Arrangement; **Movymia®** and **Sondelbay®**.

In March 2024, the MMP identified an additional BVM for teriparatide, **Tetridar®**.

The MMP recommends that when initiating a patient on a medicinal product containing teriparatide, the clinician should prescribe **Movymia®**, **Sondelbay®** or **Tetridar®**. The MMP also recommends that prescribers should give consideration to switching a patient to **Movymia®**, **Sondelbay®** or **Tetridar®** when a repeat prescription is being issued for a medicinal product containing teriparatide.

Evaluation reports, which include information on the processes followed to identify the BVMs, are available on the website of the MMP under *Best-value medicines*: www.hse.ie/yourmedicines

What changes were introduced for teriparatide from 1 March 2023?

Since 1 March 2023, it is HSE policy that all adult patients who are commencing treatment with teriparatide should be prescribed one of the MMP BVMs.

Why have these changes been introduced?

The BVMs for teriparatide are provided to the HSE at a much lower cost than the original version of teriparatide. This provides an opportunity to reduce the cost to the HSE of providing this medicine to patients. Prescribing of the BVMs will lead to significant savings for the health service, which can assist in facilitating access to new, innovative medicines for patients.

What do these changes mean for new patients, i.e. those commencing treatment with teriparatide?

All adult patients who are commencing treatment with teriparatide should be prescribed **Movymia®**, **Sondelbay®** or **Tetridar®**.

What is the definition of a new patient?

A new patient, is an adult, who has never been prescribed teriparatide before, or has not received this medicine within the last six months.

What do these changes mean for existing patients prescribed teriparatide prior to 1 March 2023?

There is currently no change for existing patients. They will continue to receive their medicine under the High Tech Arrangement from their community pharmacy.

However, when existing patients present for a repeat prescription for a medicinal product containing teriparatide, **the prescriber could consider switching the patient to Movymia®, Sondelbay® or Tetridar®**.

Do these changes apply to all patients?

These changes **do not apply to paediatric patients,** i.e. patients who are less than 18 years of age.

Where can I get information on the best-value medicines for teriparatide?

Information on the BVMs is available on the website of the MMP under *Best-value medicines*: www.hse.ie/yourmedicines

This includes support materials for clinical teams who are initiating patients on or switching them to the BVMs:

- Best-value medicine: Teriparatide. Questions and Answers for Healthcare Professionals
- Information for Patients about Medicines containing Teriparatide
- MMP product information sheets for Movymia®, Sondelbay® and Tetridar®
- Information on patient support services for Movymia®, Sondelbay® and Tetridar®
- Template switching letters for clinics

- Patient Information Leaflets on switching from Forsteo® to Movymia®, Sondelbay® or Tetridar®.

Who should I contact if I have any questions?

MMP pharmacists are available to engage with consultants and clinical teams to provide support for initiation of, and switching to the BVMs. This includes the provision of information sessions, in conjunction with the High Tech Co-ordination Unit, on the BVMs and the High Tech Hub.

Please contact the MMP (mmp@hse.ie) if you wish to avail of this support.

Movymia® and Sondelbay® are both biosimilar medicines; where can I get more information on biosimilar medicines?

Further information for both healthcare professionals and patients on biosimilar medicines is available on the following websites:

Health Products Regulatory Authority: www.hpra.ie/homepage/medicines/special-topics/biosimilar-medicines

European Medicines Agency: www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview#information-for-patients-and-healthcare-professionals-section

The European Medicines Agency issued a joint statement with the Heads of Medicines Agencies on interchangeability of biosimilar medicines in September 2022. What did this say?

This statement confirmed that biosimilar medicines approved in the EU are interchangeable with their reference medicine or with an equivalent biosimilar medicine.

Interchangeability in this context means that a prescriber can replace the reference medicine with a biosimilar medicine without a patient experiencing any changes in the clinical effect.

The European Medicines Agency highlighted that the experience obtained from clinical practice has shown that in terms of efficacy, safety and immunogenicity, biosimilar

medicines are comparable to their reference medicine and therefore can be prescribed interchangeably.

Tetridar® is a hybrid medicine; where can I get more information on hybrid medicines?

Further information on hybrid medicines is available on the website of the European Medicines Agency:

https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/generic-hybrid-medicines

Can Movymia®, Sondelbay® and Tetridar® be prescribed on the High Tech Hub?

Yes, High Tech Prescriptions for Movymia®, Sondelbay® and Tetridar® can be generated on the High Tech Hub.

Since August 2020, the High Tech Hub has been approved as a national electronic prescription transfer system.

Queries in relation to registration for the High Tech Hub should be directed to the HSE-Primary Care Reimbursement Service High Tech Co-ordination Unit at PCRS.HiTech@hse.ie.